Phentolamine Mesylate

Phase 2Small molecule

NNovalar Pharmaceuticals, Inc.

Phentolamine Mesylate is one of 68 small molecule programs targeting Erectile Dysfunction. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Erectile DysfunctionActive, not recruiting

ObesityActive, not recruiting

Erectile DysfunctionPhase 2

Active, not recruiting

ObesityPhase 1

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Actemra

Roche

Preclinical

2 2

Colcrys

Alnylam Pharmaceuticals

Amidate

Calciferol

Alnylam Pharmaceuticals

Adenocard

Activella

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

Cetrotide

EMD Serono

Preclinical

2 9

Phentolamine Mesylate

NNovalar Pharmaceuticals, Inc.

Phase 2

1 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Sex Differences

NCT05997732

Clinical

Trials by Indication[1]

Sex Differences2 trials

Sex Differences in Sympathetic Vascular Reactivity at High Altitude

Completed·UUniversity of Alberta·N/A·NCT05525416·17 enrolled

Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences

Recruiting·UUniversity of Alberta·Phase 4·NCT05997732·30 enrolled

Efficacy2 trials

Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures

Completed·NNovalar Pharmaceuticals, Inc.·Phase 3·NCT00309361·240 enrolled

Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures

Completed·NNovalar Pharmaceuticals, Inc.·Phase 3·NCT00309335·240 enrolled

Obesity1 trial

Sex Disparities in Hypoxic Vasodilation and Impact of Obesity

Recruiting·UUniversity of Missouri-Columbia·Phase 1·NCT05219799·72 enrolled

Cardiovascular1 trial

A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems

Terminated·—·Phase 1·NCT03098680·18 enrolled

Lidocaine1 trial

Reversing the Effects of 2% Lidocaine

Completed·—·N/A·NCT02861378·38 enrolled

3 more indications

Safety and Efficacy1 trial

Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures

Completed·NNovalar Pharmaceuticals, Inc.·Phase 2·NCT00309322·150 enrolled

Blood Pressure1 trial

Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage

Completed·TThe George Institute·N/A·NCT00226096·404 enrolled

Erectile Dysfunction1 trial

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00080808·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Phentolamine Mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phentolamine Mesylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phentolamine Mesylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novalar Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNovalar Pharmaceuticals, Inc.

Phentolamine Mesylate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Sex Differences2 trials

Efficacy2 trials

Obesity1 trial

Cardiovascular1 trial

Lidocaine1 trial

Safety and Efficacy1 trial

Blood Pressure1 trial

Erectile Dysfunction1 trial

References

Drug Info

Quick Facts

Related News